$HBIO
HARVARD BIOSCIENCE INC Stock $hbio

$hbio Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-Q Financial Statement

#000117184319003099 Filed on May 08, 2019

Income Statement

Concept	2019 Q1	2018 Q1
Revenue	$28.20M	$26.76M
YoY Change	5.39%	47.95%
Cost Of Revenue	$12.05M	$13.49M
YoY Change	-10.69%	58.54%
Gross Profit	$16.15M	$13.27M
YoY Change	21.74%	38.55%
Gross Profit Margin	57.28%	49.59%
Selling, General & Admin	$12.11M	$11.03M
YoY Change	9.78%	33.44%
% of Gross Profit	74.96%	83.13%
Research & Development	$2.735M	$2.402M
YoY Change	13.86%	86.93%
% of Gross Profit	16.93%	18.1%
Depreciation & Amortization	$538.0K	$495.0K
YoY Change	8.69%	61.76%
% of Gross Profit	3.33%	3.73%
Operating Expenses	$16.27M	$14.54M
YoY Change	11.96%	46.42%
Operating Profit	-$120.0K	-$1.266M
YoY Change	-90.52%	261.71%
Interest Expense	-$1.405M	$894.0K
YoY Change	-257.16%	448.47%
% of Operating Profit
Other Income/Expense, Net	-$1.674M	-$3.979M
YoY Change	-57.93%	894.75%
Pretax Income	-$1.794M	-$5.245M
YoY Change	-65.8%	599.33%
Income Tax	$576.0K	$605.0K
% Of Pretax Income
Net Earnings	-$2.370M	-$4.064M
YoY Change	-41.68%	281.24%
Net Earnings / Revenue	-8.4%	-15.19%
Basic Earnings Per Share	-$0.06	-$0.11
Diluted Earnings Per Share	-$0.06	-$0.11
COMMON SHARES
Basic Shares Outstanding	37.64M	35.46M shares
Diluted Shares Outstanding	37.64M	35.46M shares

Balance Sheet

Concept	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.000M	$6.000M
YoY Change	-16.67%	30.43%
Cash & Equivalents	$5.030M	$5.991M
Short-Term Investments
Other Short-Term Assets		$2.959M
YoY Change		-37.85%
Inventory	$26.56M	$27.90M
Prepaid Expenses
Receivables	$18.79M	$18.96M
Other Receivables	$3.200M	$2.900M
Total Short-Term Assets	$53.60M	$55.81M
YoY Change	-3.96%	23.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.70M	$5.821M
YoY Change	152.53%	36.39%
Goodwill	$57.38M	$56.24M
YoY Change	2.02%	46.46%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.500M	$1.352M
YoY Change	10.95%	838.89%
Total Long-Term Assets	$117.7M	$115.1M
YoY Change	2.27%	84.75%
TOTAL ASSETS
Total Short-Term Assets	$53.60M	$55.81M
Total Long-Term Assets	$117.7M	$115.1M
Total Assets	$171.3M	$170.9M
YoY Change	0.23%	59.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.311M	$7.359M
YoY Change	-0.65%	26.12%
Accrued Expenses	$7.700M	$7.689M
YoY Change	0.14%	77.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.200M	$1.400M
YoY Change	57.14%	-48.15%
Total Short-Term Liabilities	$24.10M	$22.28M
YoY Change	8.15%	58.54%
LONG-TERM LIABILITIES
Long-Term Debt	$54.10M	$61.57M
YoY Change	-12.13%	463.25%
Other Long-Term Liabilities	$10.40M	$6.100M
YoY Change	70.49%	90.63%
Total Long-Term Liabilities	$64.50M	$61.57M
YoY Change	4.76%	463.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.10M	$22.28M
Total Long-Term Liabilities	$64.50M	$61.57M
Total Liabilities	$91.00M	$91.65M
YoY Change	-0.71%	164.27%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock		$220.4M
YoY Change		1.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	7.746M shares	7.746M shares
Shareholders Equity	$80.35M	$79.29M
YoY Change
Total Liabilities & Shareholders Equity	$171.3M	$170.9M
YoY Change	0.21%	59.17%

Cashflow Statement

Concept	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$2.370M	-$4.064M
YoY Change	-41.68%	281.24%
Depreciation, Depletion And Amortization	$538.0K	$495.0K
YoY Change	8.69%	61.76%
Cash From Operating Activities	$2.010M	$448.0K
YoY Change	348.66%	-173.44%
INVESTING ACTIVITIES
Capital Expenditures	$143.0K	$493.0K
YoY Change	-70.99%	148.99%
Acquisitions	$0.00	$67.41M
YoY Change	-100.0%
Other Investing Activities	$9.000K	-$51.68M
YoY Change	-100.02%
Cash From Investing Activities	-$152.0K	-$52.19M
YoY Change	-99.71%	22789.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$421.0K	$219.0K
YoY Change	-292.24%	-241.29%
Debt Paid & Issued, Net	$4.583M	$14.05M
YoY Change	-67.37%	1162.08%
Cash From Financing Activities	-5.004M	$51.24M
YoY Change	-109.77%	-19220.9%
NET CHANGE
Cash From Operating Activities	2.010M	$448.0K
Cash From Investing Activities	-152.0K	-$52.19M
Cash From Financing Activities	-5.004M	$51.24M
Net Change In Cash	-3.143M	-$497.0K
YoY Change	532.39%	-55.06%
FREE CASH FLOW
Cash From Operating Activities	$2.010M	$448.0K
Capital Expenditures	$143.0K	$493.0K
Free Cash Flow	$1.867M	-$45.00K
YoY Change	-4248.89%	-94.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7679000	USD
CY2019Q1	dei	Trading Symbol TradingSymbol	HBIO
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2019Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	7745507	shares
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37687608	shares
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	HARVARD BIOSCIENCE INC
CY2018Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5646000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5384000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2402000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-347000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	894000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2738000	USD
CY2019Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	3834000	USD
CY2019Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	15044000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23683000	USD
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18101000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2297000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2268000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1862000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1813000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1795000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6970000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	17005000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5600000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	5600000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	5600000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	5500000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	5400000	USD
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	4000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1506000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-196000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-254000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-17000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	25000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2545000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2837000	USD
CY2019Q1	hbio	Total Indefinite Lived Intangible Assets Including Goodwill TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill	58603000	USD
CY2019Q1	hbio	Total Intangible Assets TotalIntangibleAssets	131817000	USD
CY2019Q1	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	132000	USD
CY2019Q1	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	182000	USD
CY2019Q1	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-76000	USD
CY2019Q1	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	26000	USD
CY2018	hbio	Standard Product Warranty Accrual Decrease For Payments Or Increase For Credits StandardProductWarrantyAccrualDecreaseForPaymentsOrIncreaseForCredits	37000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	16120000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	34000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1828000	USD
CY2018	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	182000	USD
CY2019Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-17000	USD
CY2019Q1	us-gaap	Secured Debt SecuredDebt	56342000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23336000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17438000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	73214000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-30223000	USD
CY2018Q4	hbio	Total Indefinite Lived Intangible Assets Including Goodwill TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill	58536000	USD
CY2018Q4	hbio	Total Intangible Assets TotalIntangibleAssets	131887000	USD
CY2018Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	391000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	383827	shares
CY2019Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2018Q2	hbio	Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan IncreaseInNumberOfSharesAuthorizedForIssuanceUnderStockOptionAndIncentivePlan	3400000	shares
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	73351000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-28819000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1956732	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1233762	shares
CY2019Q1	hbio	Standard Product Warranty Accrual Decrease For Payments Or Increase For Credits StandardProductWarrantyAccrualDecreaseForPaymentsOrIncreaseForCredits	22000	USD
CY2019Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	1000	USD
CY2018Q1	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	132000	USD
CY2018Q1	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	204000	USD
CY2018Q1	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-58000	USD
CY2018Q1	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	-14000	USD
CY2019Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000	USD
CY2018Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	900000	USD
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3691304	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	20908929	shares
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	591000	USD
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1794000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	576000	USD
CY2019Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2500	shares
CY2019Q1	hbio	Employee Stock Purchase Plan Shares Authorized EmployeeStockPurchasePlanSharesAuthorized	1050000	shares
CY2019Q1	us-gaap	Revenues Revenues	28202000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12048000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	16154000	USD
CY2018Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5000	USD
CY2018Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	276000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2018Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1012000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	495000	USD
CY2018Q1	hbio	Amortization Of Catalog Costs AmortizationOfCatalogCosts	6000	USD
CY2018Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1354000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-149000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-799000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-650000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1346000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	173000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	850000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	429000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-247000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	448000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-52189000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	67000000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	219000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51244000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	755000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	258000	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	944000	USD
CY2018Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-489000	USD
CY2018Q1	hbio	Additions To Catalog Costs AdditionsToCatalogCosts	-13000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13532000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13707000	USD
CY2019Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	71000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-175000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-192000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21463000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	25087000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18788000	USD
CY2019Q1	us-gaap	Inventory Net InventoryNet	26557000	USD
CY2019Q1	us-gaap	Goodwill Goodwill	57375000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	57304000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	44532000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	42991000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7359000	USD
CY2019Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	2207000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7311000	USD
CY2019Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	57817000	USD
CY2019Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1475000	USD
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.26
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1430000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate	0.85	pure
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4899228	shares
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	493000	USD
CY2018Q4	us-gaap	Assets Assets	168613000	USD
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	978000	USD
CY2018Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1232000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3109000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	211000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	57832000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1604000	USD
CY2018Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	5982000	USD
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3820000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5762000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1588000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25489000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	54813000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2301000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	3286000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	85889000	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	436000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	226377000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119889000	USD
CY2018Q4	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	10668000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	168613000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8173000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	82724000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5898000	USD
CY2018Q1	us-gaap	Revenues Revenues	26759000	USD
CY2019Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	0	USD
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13490000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	13269000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	14535000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1266000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3979000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5245000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	605000	USD
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2019Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-2370000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-5850000	USD
CY2019Q1	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0	USD
CY2018Q1	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-873000	USD
CY2019Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-2370000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.06
CY2018Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.16
CY2019Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.05
CY2019Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.06
CY2018Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.16
CY2019Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.05
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37644684	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37644684	shares
CY2019Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	591000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	538000	USD
CY2019Q1	hbio	Amortization Of Catalog Costs AmortizationOfCatalogCosts	5000	USD
CY2019Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-16000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	91000	USD
CY2019Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2695000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1416000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	380000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-76000	USD
CY2019Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-116000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-143000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2010000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-152000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-421000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3143000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	927000	USD
CY2019Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	94000	USD
CY2019Q1	hbio	Additions To Catalog Costs AdditionsToCatalogCosts	-9000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	143000	USD
CY2019Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2018Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	1227000	USD
CY2019Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2018Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	67413000	USD
CY2019Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	USD
CY2018Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	15730000	USD
CY2019Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4583000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	14047000	USD
CY2019Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2018Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1928000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6936000	USD
CY2019Q1	us-gaap	Reclassifications Reclassifications	<div><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:27pt;' >R</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;' >eclassifications</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:36pt;' >As disclosed in Note 5, on January 22, 2018, the Company sold substantially all the assets of its operating subsidiary, Denville Scientific, Inc. (Denville). The sale of Denville represented a strategic shift that </font><font style='font-family:Times New Roman;font-size:10pt;' >had</font><font style='font-family:Times New Roman;font-size:10pt;' > a major effect on the Company’s operat</font><font style='font-family:Times New Roman;font-size:10pt;' >ions</font><font style='font-family:Times New Roman;font-size:10pt;' > and financial results. As such and pursuant to Accounting Standards Codification (ASC) 205-20 – </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Presentation of Financial Statements - Discontinued Operations, </font><font style='font-family:Times New Roman;font-size:10pt;' >the </font><font style='font-family:Times New Roman;font-size:10pt;' >operating </font><font style='font-family:Times New Roman;font-size:10pt;' >results of Denville for the </font><font style='font-family:Times New Roman;font-size:10pt;' >three months ended</font><font style='font-family:Times New Roman;font-size:10pt;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >March 31,</font><font style='font-family:Times New Roman;font-size:10pt;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >2018</font><font style='font-family:Times New Roman;font-size:10pt;' > have </font><font style='font-family:Times New Roman;font-size:10pt;' >been presented in discontinued operations in the consolidated statements of operations. T</font><font style='font-family:Times New Roman;font-size:10pt;' >hese reclassifications and adjustments had no effect on</font><font style='font-family:Times New Roman;font-size:10pt;' > total amounts within the</font><font style='font-family:Times New Roman;font-size:10pt;' > consolidated </font><font style='font-family:Times New Roman;font-size:10pt;' >balance sheet, </font><font style='font-family:Times New Roman;font-size:10pt;' >consolidated statements of </font><font style='font-family:Times New Roman;font-size:10pt;' >operations and </font><font style='font-family:Times New Roman;font-size:10pt;' >comprehensive </font><font style='font-family:Times New Roman;font-size:10pt;' >in</font><font style='font-family:Times New Roman;font-size:10pt;' >come (</font><font style='font-family:Times New Roman;font-size:10pt;' >loss</font><font style='font-family:Times New Roman;font-size:10pt;' >)</font><font style='font-family:Times New Roman;font-size:10pt;' >, consolidated statements of cash flows for any of the periods presented.</font></p><p style='text-align:left;line-height:12pt;' ></p></div>
CY2018Q1	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	71100000	USD
CY2019Q1	us-gaap	Business Acquisition Description Of Acquired Entity BusinessAcquisitionDescriptionOfAcquiredEntity	DSI, a St. Paul, Minnesota-based life science research company, is a recognized leader in physiologic monitoring focused on delivering preclinical products, systems, services and solutions to its customers.
CY2019Q1	us-gaap	Business Acquisition Effective Date Of Acquisition1 BusinessAcquisitionEffectiveDateOfAcquisition1	2018-01-31
CY2018Q1	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	7600000	USD
CY2018Q1	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	400000	USD
CY2018Q1	hbio	Busniess Combination Purchase Accounting Inventory Fair Value Step Up Amortization BusniessCombinationPurchaseAccountingInventoryFairValueStepUpAmortization	1500000	USD
CY2018Q1	hbio	Preliminary Amount Of Inventory Fair Value Step Up PreliminaryAmountOfInventoryFairValueStepUp	3800000	USD
CY2018Q1	hbio	Business Combination Proforma Information Amortization Of Intangible Asets BusinessCombinationProformaInformationAmortizationOfIntangibleAsets	700000	USD
CY2019Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	0	USD
CY2018Q1	us-gaap	Discontinued Operation Name DiscontinuedOperationName	Denville
CY2018Q1	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	20000000	USD
CY2018Q1	hbio	Earn Out Provision Of Discontinued Operations EarnOutProvisionOfDiscontinuedOperations	3000000	USD
CY2018Q1	hbio	Discontinued Operation Earn Out Amount Contingent Consideration DiscontinuedOperationEarnOutAmountContingentConsideration	3000000	USD
CY2019Q1	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	0	USD
CY2018Q1	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	893000	USD
CY2019Q1	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	0	USD
CY2018Q1	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	534000	USD
CY2019Q1	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	0	USD
CY2018Q1	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	673000	USD
CY2019Q1	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0	USD
CY2018Q1	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	1227000	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3667000	USD
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	14484000	USD
CY2019Q1	us-gaap	Defined Benefit Plan Expected Future Employer Contributions Remainder Of Fiscal Year DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear	500000	USD
CY2019Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-12-31
CY2019Q1	us-gaap	Deferred Compensation Arrangement With Individual Maximum Contractual Term1 DeferredCompensationArrangementWithIndividualMaximumContractualTerm1	P10Y
CY2019Q1	hbio	Amortization Of Intangible Assets Including Amounts Related To Discontinued Operation AmortizationOfIntangibleAssetsIncludingAmountsRelatedToDiscontinuedOperation	1430000	USD
CY2018Q1	hbio	Amortization Of Intangible Assets Including Amounts Related To Discontinued Operation AmortizationOfIntangibleAssetsIncludingAmountsRelatedToDiscontinuedOperation	1150000	USD
CY2019Q1	hbio	Maximum Percentage Of Target Number Of Restricted Stock Units MaximumPercentageOfTargetNumberOfRestrictedStockUnits	1.5	pure
CY2018Q4	us-gaap	Secured Debt SecuredDebt	60795000	USD
CY2018Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	62400000	USD
CY2018Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1605000	USD
CY2019Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	393000	USD
CY2018Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	401000	USD
CY2019Q1	us-gaap	Loans Payable Current LoansPayableCurrent	2600000	USD
CY2018Q4	us-gaap	Loans Payable Current LoansPayableCurrent	6383000	USD
CY2018Q1	us-gaap	Line Of Credit LineOfCredit	11900000	USD
CY2018Q1	us-gaap	Debt Instrument Payment Terms DebtInstrumentPaymentTerms	the outstanding term loans began to amortize in equal quarterly installments equal to $0.4 million per quarter on such date and during each of the next three quarters thereafter, $0.6 million per quarter during the next four quarters thereafter and $0.8 million per quarter thereafter, with a balloon payment at maturity.
CY2018Q1	hbio	Debt Instrument Quarterly Payment Current Year DebtInstrumentQuarterlyPaymentCurrentYear	400000	USD
CY2018Q1	hbio	Debt Instrument Quarterly Payment Next Year DebtInstrumentQuarterlyPaymentNextYear	600000	USD
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q1	hbio	Debt Instrument Quarterly Payment Thereafter DebtInstrumentQuarterlyPaymentThereafter	800000	USD
CY2019Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P5Y
CY2019Q1	hbio	Limitation On Pledges Of Capital Stock Of Foreign Subsidiaries LimitationOnPledgesOfCapitalStockOfForeignSubsidiaries	0.65	pure
CY2018Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	25000000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	332000	USD
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45124309	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37378802	shares
CY2018Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7745507	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	370000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35462989	shares
CY2018Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35462989	shares
CY2019Q1	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	1.58
CY2018Q4	us-gaap	Deferred Revenue DeferredRevenue	3820000	USD
CY2019Q1	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	956000	USD
CY2019Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	1071000	USD
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	10000	USD
CY2019Q1	us-gaap	Deferred Revenue DeferredRevenue	3715000	USD
CY2018Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.115	pure
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q1	us-gaap	Employee Stock Ownership Plan Esop Shares In Esop EmployeeStockOwnershipPlanESOPSharesInESOP	890762	shares
CY2019Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2019Q1	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	100000	USD
CY2018Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	2600000	USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2018Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2019Q1	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments	0	USD
CY2018Q1	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments	0	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2439141	shares
CY2018Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	4.25
CY2019Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	4.13
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.36
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.56
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1082205	shares
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1012000	USD
CY2019Q1	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div><p style='text-align:left;margin-top:9pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0pt;' >2</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;' >.</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;' > Recently Issued Accounting Pronouncements</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Calibri;font-size:11pt;font-weight:bold;margin-left:0pt;' > </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >In June 2016, the FASB issued ASU No. 2016-13, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > which amends the impairment model by requiring entities </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. Th</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >e ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >provided additional implementation guidance on the previously issued ASU. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements. Currently, the Company believes that the most no</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >table impact of this ASU will relate to its processes around the assessment of the adequacy of its allowance for doubtful accounts on trade accounts receivable and the recognition of credit losses.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >In August 2018, the FASB issued ASU No. 2018-14, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >Disclosu</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >re Framework—Changes to the Disclosure Requirements for Defined Benefit Plans</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >, which amends ASC 715 to add, remove and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The ASU is effective for public entiti</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >es for fiscal years beginning after December 15, 2020, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:24.5pt;' >Recently Adopted Accounting Pronoun</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >cements</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' > </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In August</font><font style='font-family:Times New Roman;font-size:10pt;' > 201</font><font style='font-family:Times New Roman;font-size:10pt;' >7, the FASB issued ASU 2017-12, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Derivatives and Hedging (Topic 815)</font><font style='font-family:Times New Roman;font-size:10pt;' > which amends the hedge accounting recognition and presentation requirements in ASC 815</font><font style='font-family:Times New Roman;font-size:10pt;' >, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Derivatives and Hedging</font><font style='font-family:Times New Roman;font-size:10pt;' >. The Board’s objectives in issuing the ASU are to (1)</font><font style='font-family:Times New Roman;font-size:10pt;' > improve the transparency and understandability of information conveyed to financial statement users about an entity’s risk management activities by better aligning the entity’s financial reporting for hedging relationships with those risk management activ</font><font style='font-family:Times New Roman;font-size:10pt;' >ities and (2) reduce the complexity of and simplify the application o</font><font style='font-family:Times New Roman;font-size:10pt;' >f hedge accounting by preparers. The</font><font style='font-family:Times New Roman;font-size:10pt;' > ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 201</font><font style='font-family:Times New Roman;font-size:10pt;' >8. The</font><font style='font-family:Times New Roman;font-size:10pt;' > Company adopted this</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > guidance as of January 1, 2019, and it did not have a material impact on its consolidated financial position, results of operations and cash flows.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Leases</font><font style='font-family:Times New Roman;font-size:10pt;' >, </font><font style='font-family:Times New Roman;font-size:10pt;' >which is intended to improve financial reporting about leasing transactions. The update requires a lessee to record on its balance sheet the assets and liabilities for the rights and obligations created by lease terms of more than 12 months. The update is </font><font style='font-family:Times New Roman;font-size:10pt;' >effective for fiscal years beginning after December 15, 2018. </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, wi</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >th certain practical expedients available. T</font><font style='font-family:Times New Roman;font-size:10pt;' >he Company </font><font style='font-family:Times New Roman;font-size:10pt;' >elected</font><font style='font-family:Times New Roman;font-size:10pt;' > to utilize a practical expedient in its method of adoption of the standard</font><font style='font-family:Times New Roman;font-size:10pt;' > and adopted the guidance as of January 1, 2019</font><font style='font-family:Times New Roman;font-size:10pt;' >.  Under this expedient, which is a “current-period adjustment method,” </font><font style='font-family:Times New Roman;font-size:10pt;' >the Company </font><font style='font-family:Times New Roman;font-size:10pt;' >applied</font><font style='font-family:Times New Roman;font-size:10pt;' > ASC 842 as of January 2019 and</font><font style='font-family:Times New Roman;font-size:10pt;' > recognized operating lease liabilities of $</font><font style='font-family:Times New Roman;font-size:10pt;' >11.7 </font><font style='font-family:Times New Roman;font-size:10pt;' >million and right of use assets of $</font><font style='font-family:Times New Roman;font-size:10pt;' >9.4 </font><font style='font-family:Times New Roman;font-size:10pt;' >million for all leases with lease terms of more than 12 months. There was no impact</font><font style='font-family:Times New Roman;font-size:10pt;' > to retained earnings as of that d</font><font style='font-family:Times New Roman;font-size:10pt;' >ate.</font><font style='font-family:Times New Roman;font-size:10pt;' > In addition, the Company adopted the guidance by electing the following practical expedients: (1) the Company did not reassess whether any expired or existing contracts contained leases,</font><font style='font-family:Times New Roman;font-size:10pt;' > (2) the Company did not reassess the lease classification fo</font><font style='font-family:Times New Roman;font-size:10pt;' >r any expired or existing leases, and (3) the Company excluded variable payments from the lease contract consideration and recorded those as incurred</font><font style='font-family:Times New Roman;font-size:10pt;' >. </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >The Company’s future commitments under lease obligations and additional disclosures are summarized in Note 12.</font></p><p style='text-align:left;line-height:12pt;' ></p></div>
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001123494
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9106000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2297000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9062000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	82724000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-421000	USD
CY2019Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	440000	shares
CY2019Q1	hbio	Shareswithheldfortaxesshares Shareswithheldfortaxesshares	134000	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	80900000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	817000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-5000	USD
CY2018Q1	hbio	Shares Withheld For Taxes Value SharesWithheldForTaxesValue	603000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-4064000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	79294000	USD
CY2017Q4	us-gaap	Shares Issued SharesIssued	42764000	shares
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	298000	shares
CY2018Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	532000	shares
CY2018Q1	hbio	Shareswithheldfortaxesshares Shareswithheldfortaxesshares	185000	shares
CY2018Q1	us-gaap	Shares Issued SharesIssued	43409000	shares
CY2018Q1	hbio	Earn Out Performance Metrics Period EarnOutPerformanceMetricsPeriod	P2Y
CY2018Q4	us-gaap	Goodwill Goodwill	57304000	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1103000	USD
CY2019Q1	hbio	Effective Income Tax Rate Reconciliation Reduction In Tax Rate From Tax Cuts And Jobs Act Of2017 EffectiveIncomeTaxRateReconciliationReductionInTaxRateFromTaxCutsAndJobsActOf2017	0.21	pure
CY2017Q4	us-gaap	Deferred Revenue DeferredRevenue	505000	USD
CY2018Q1	hbio	Deferred Revenue Additions Due To Business Combination DeferredRevenueAdditionsDueToBusinessCombination	2977000	USD
CY2018Q1	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	1321000	USD
CY2018Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	954000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	4000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	332000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	193000	USD
CY2019Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	27000	USD
CY2018Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2019Q1	hbio	Allowance For Doubtful Accounts Receivable Other AllowanceForDoubtfulAccountsReceivableOther	0	USD
CY2018Q1	hbio	Allowance For Doubtful Accounts Receivable Other AllowanceForDoubtfulAccountsReceivableOther	36000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	-2000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	0	USD
CY2019Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	341000	USD
CY2018Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	234000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	523000	USD
CY2019Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	76000	USD
CY2019Q1	us-gaap	Sublease Income SubleaseIncome	102000	USD
CY2019Q1	us-gaap	Lease Cost LeaseCost	497000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	702000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	11359000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y7M6D
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.092	pure
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9400000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	11700000	USD
CY2018Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
CY2017Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	246000	USD
CY2018Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	913000	USD
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	1786000	USD
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.8
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.8
CY2018Q4	us-gaap	Shares Issued SharesIssued	45124000	shares
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8173000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5733000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5991000	USD
CY2019Q1	us-gaap	Immaterial Error Correction ImmaterialErrorCorrection	The immaterial misclassification understated current portion, long term debt and overstated long term debt, less current installments. This misclassification, in the amount of approximately $4.0 million, related to the classification of the Company’s excess cash flow payment made to its lenders during the quarter ended March 31, 2019 as long term instead of current on its consolidated balance sheet at December 31, 2018. The misclassification had no impact on total reported debt.

Files In Submission

Name	View Source	Status
0001171843-19-003099-index-headers.html	Edgar Link	pending
0001171843-19-003099-index.html	Edgar Link	pending
0001171843-19-003099.txt	Edgar Link	pending
0001171843-19-003099-xbrl.zip	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
f10q_050719.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hbio-20190331.xml	Edgar Link	completed
hbio-20190331.xsd	Edgar Link	pending
hbio-20190331_cal.xml	Edgar Link	unprocessable
hbio-20190331_def.xml	Edgar Link	unprocessable
hbio-20190331_lab.xml	Edgar Link	unprocessable
hbio-20190331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HBIO
HARVARD BIOSCIENCE INC Stock $hbio

2019 Q1 Form 10-Q Financial Statement

#000117184319003099 Filed on May 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HBIO HARVARD BIOSCIENCE INC Stock $hbio

2019 Q1 Form 10-Q Financial Statement

#000117184319003099 Filed on May 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HBIO
HARVARD BIOSCIENCE INC Stock $hbio